{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:41:00Z","timestamp":1769128860730,"version":"3.49.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":2143,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","award":["ALFGBG-878221"],"award-info":[{"award-number":["ALFGBG-878221"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish government and the country councils, the ALF-agreement"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","award":["ALFGBG\u2010878221"],"award-info":[{"award-number":["ALFGBG\u2010878221"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sacubitril\/Valsartan (Sac\/Val) was proven more effective than enalapril for symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This study aimed to investigate eligibility, titration, and tolerability for Sac\/Val in a real-world clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This retrospective cohort study consists of two parts. In Part 1 (eligibility study), all patients discharged from Sahlgrenska University Hospital due to HF were consecutively included during 1 year. Data from the patients' medical records were collected. Patients were adjudicated to be eligible based on European Society of Cardiology (ESC) criteria for angiotensin receptor neprilysin inhibitor (ARNI) with the exception of N-terminal (NT)-proBNP levels. Patients who received &amp;lt;50% of target dose angiotensin-converting enzyme\/angiotensin receptor blocker and otherwise fulfilled ESC criteria were adjudicated to be potentially eligible. In Part 2 (tolerability study), all patients receiving Sac\/Val during the same period were included. Medical data regarding dose, titration, and adverse effects and events were registered. A total of 1355 patients (mean age 78 \u00b1 13 years) were hospitalized for HF and 619 patients had an EF \u226440%. Twenty percent were eligible for initiation of ARNI, and additionally 8% were potentially eligible. In all 95 patients (mean age 65 \u00b1 12 years) were initiated with Sac\/Val, which correlates to 13%. The patients who were initiated were younger (65 years), more often had dilated cardiomyopathy (31%), more often were on guideline-directed medical therapy, and had a higher frequency of cardiac resynchronization therapy and implantable cardioverter\u2013defibrillator compared with the patients who did not receive Sac\/Val. Of the initiated patients, 59% reached target dose of Sac\/Val, and 15% discontinued due to adverse effects. The most common cause of discontinuation was benign gastrointestinal adverse effects, followed by elevated creatinine, malaise, and vertigo. Female gender [odds ratio (OR) 3.58; 95% CI 1.07\u20132.00; P = 0.038] and NT-proBNP \u2265 median level (OR 0.48; 95% CI 0.26\u20130.90; P = 0.021) was associated with termination of the medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among HFrEF patients in this real-world cohort, 20% were eligible for ARNI; however, only 13% received the treatment. Sac\/Val was well tolerated, but 41% of the patients did not reach target dose. How this affects outcome is not known and needs further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12644","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T01:58:15Z","timestamp":1581040695000},"page":"1049-1055","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Early Experience of Sacubitril\u2013Valsartan in Heart Failure with Reduced Ejection Fraction in Real-world Clinical Setting"],"prefix":"10.1093","volume":"7","author":[{"given":"Charlotte","family":"Nordberg Backelin","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Medicine\/Cardiology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine\/Cardiology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotta","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine\/Cardiology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , G\u00f6teborg ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"2026012115042896400_ehf212644-bib-0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0002","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd","year":"2007","journal-title":"Heart"},{"key":"2026012115042896400_ehf212644-bib-0003","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0004","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ejhf.109","article-title":"Trends in prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden","volume":"16","author":"Paren","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.5603\/KP.2016.0141","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"74","author":"Ponikowski","year":"2016","journal-title":"Kardiol Pol"},{"key":"2026012115042896400_ehf212644-bib-0006","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115042896400_ehf212644-bib-0007","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0008","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2026012115042896400_ehf212644-bib-0009","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026012115042896400_ehf212644-bib-0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ehf2.12251","article-title":"Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study","volume":"5","author":"Norberg","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0011","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ejhf.788","article-title":"What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?","volume":"19","author":"Pellicori","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0012","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ejhf.1532","article-title":"Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency\/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world","volume":"27","author":"Kapelios","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0013","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10557-019-06873-1","article-title":"\u201cReal world\u201d eligibility for Sacubitril\/Valsartan in unselected heart failure patients: data from the Swedish Heart Failure Registry","volume":"33","author":"Simpson","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012115042896400_ehf212644-bib-0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2459\/JCM.0000000000000889","article-title":"The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016","volume":"21","author":"Chen","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026012115042896400_ehf212644-bib-0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jcma.2017.04.011","article-title":"Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry","volume":"80","author":"Chang","year":"2017","journal-title":"J Chin Med Assoc"},{"key":"2026012115042896400_ehf212644-bib-0016","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0017","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003212","article-title":"Effects of Sacubitril\/Valsartan in the PARADIGM-HF Trial (Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure) according to background therapy","volume":"9","author":"Okumura","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0018","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0019","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Prospective Comparison of AwAtDIoGM, Morbidity in Heart Failure I. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115042896400_ehf212644-bib-0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115042896400_ehf212644-bib-0021","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"}],"updated-by":[{"DOI":"10.1002\/ehf2.15211","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000}}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12644","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/3\/1049\/65805648\/eschf_7_3_1049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/3\/1049\/65805648\/eschf_7_3_1049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:05:20Z","timestamp":1769025920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/3\/1049\/8373054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,6]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12644","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,2,6]]},"assertion":[{"value":"2019-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}